206 related articles for article (PubMed ID: 37171752)
1. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
Giofrè C; Fabbrocini G; Potenza C; Tiberio R; Gisondi P; Marasca C; Nuzzo CMA; Benincasa E; Bianchi L;
Adv Ther; 2023 Jul; 40(7):3021-3037. PubMed ID: 37171752
[TBL] [Abstract][Full Text] [Related]
2. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
Jullien D; Richard MA; Halioua B; Bessette C; Derancourt C; Bouloc A
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1361-1376. PubMed ID: 37204608
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Ghislain PD; Lambert J; Lam Hoai XL; Hillary T; Roquet-Gravy PP; de la Brassinne M; Segaert S
Adv Ther; 2022 Feb; 39(2):1068-1080. PubMed ID: 34977985
[TBL] [Abstract][Full Text] [Related]
4. Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe.
Cetkovská P; Dediol I; Šola M; Kojanová M; Trčko K; Čarija A; Čeović R; Ledić-Drvar D; Kaštelan M; Hrabar A; Missoup MC; Mamun K
Adv Ther; 2023 Apr; 40(4):1787-1802. PubMed ID: 36862361
[TBL] [Abstract][Full Text] [Related]
5. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
[TBL] [Abstract][Full Text] [Related]
7. Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
Klein TM; Blome C; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Cordey M; Griffiths CEM; Augustin M
Dermatol Ther (Heidelb); 2022 Jan; 12(1):81-95. PubMed ID: 34813044
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
13. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy.
Licata G; Tancredi V; Gambardella A; Megna M; Fabbrocini G; Raimondo A; Lembo S; Ligrone L; Cusano F; Argenziano G
Ital J Dermatol Venerol; 2023 Dec; 158(6):452-456. PubMed ID: 37721774
[TBL] [Abstract][Full Text] [Related]
18. Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K; Korge B; Magnolo N; Manasterski M; Schwichtenberg U; Staubach-Renz P; Kaiser S; Roemmler-Zehrer J; Gómez NN; Lorenz-Baath K
Dermatol Ther (Heidelb); 2022 Jan; 12(1):203-221. PubMed ID: 34913153
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
